36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO.
(2024) Hypertension Research — Vol. 47, n° 12, p. 3467-3472 (2024)
Files
2024_Bloch_Hypertens_Res.pdf
Open Access - Adobe PDF
- 1020.61 KB
Details
- Authors
- Abstract
- Endovascular ultrasound renal denervation (uRDN) reduced blood pressure (BP) compared to sham at 2 months in patients with resistant hypertension in the multicenter, blinded, randomized, sham-controlled RADIANCE-HTN TRIO trial. This analysis evaluates longer-term outcomes of patients randomized to uRDN. Patients with resistant hypertension to a 3-drug combination pill were randomized to uRDN (n = 69) or sham (n = 67). From 2-5 months, patients followed a standardized anti-hypertensive medication (AHM) titration protocol. At 6 months, patients were unblinded and received AHM per standard of care. In the uRDN group, 71% (49/69) completed 36-month follow-up. Screening office BP was 159/103 on 3.9 AHM. Baseline office BP on the single-pill combination was 153/99 mmHg. At 36 months, office BP changed by -14.5 ± 26.1/-9.0 ± 14.8 mmHg from screening (p < 0.001 for both) and -8.0 ± 24.5/-5.0 ± 14.6 mmHg from baseline (p = 0.007; p = 0.022) on 3.7 AHM. The efficacy of uRDN was durable to 36 months in patients with resistant hypertension with no safety concerns.
- Affiliations
Citations
Bloch, M. J., Kirtane, A. J., Azizi, M., Mahfoud, F., Basile, J., Daemen, J., Saxena, M., Thackeray, L., McGuire, M., Claude, L., & Schmieder, R. E. (2024). 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertension Research, 47(12), 3467-3472. https://doi.org/10.1038/s41440-024-01854-w (Original work published 2024)